Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world study

BACKGROUND: A survival benefit has been seen for both adjuvant nab-paclitaxel plus gemcitabine (AG) and S-1 chemotherapy compared to gemcitabine (GEM) for resectable pancreatic cancer in the APACT (2019) and JASPAC01 trials (2016), respectively. However, supporting evidence regarding the effectivene...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Haorui, Guo, Yu, Sun, Xugang, Lu, Yang, Chang, Shaofei, Wang, Xiuchao, Gao, Song, Gao, Chuntao, Zhao, Tiansuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613992/
https://www.ncbi.nlm.nih.gov/pubmed/37909023
http://dx.doi.org/10.3389/fonc.2023.1276037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613992/
https://www.ncbi.nlm.nih.gov/pubmed/37909023
http://dx.doi.org/10.3389/fonc.2023.1276037

Ejemplares similares